ZIA CP010144-07160 (ZIA) | |||
---|---|---|---|
Title | ITCLC Familial Testicular Cancer Projects | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Greene, Mark | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $126,700 | Project Dates | 07/01/2002 - N/A |
Fiscal Year | 2012 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Testes (100.0%) | ||
Research Type | |||
Cancer Related Biology Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
The Clinical Genetics Branch has become a member of the International Testicular Cancer Linkage Consortium ("ITCLC"), a scientific collaboration dedicated to mapping and cloning the genes related to testicular cancer susceptibility in humans. There are three components to our collaboration with the ITCLC: 1. We are contributing DNA from newly-ascertained US testicular cancer families to this international gene identification effort. 2. We are capitalizing on the large set of European families which has already been assembled by the ITCLC by taking the scientific lead in designing and conducting two additional studies: (a) a centralized review of the pathology of a large series of familial testicular cancers and a comparison group of non-familial testicular cancers. (b) a formal, quantitative analysis of the occurrence of cancers other than testicular cancer in these families. 3. We have published a descriptive analysis of the ITCLC testicular cancer family set (n=500), the largest collection of multiple-case families extant. The goal of this project was to identify etiologically homogenous subsets of families which might be more amenable to linkage-based gene discovery. In general, the risk factor profile of familial TGCT cases was surprisingly similar to that of sporadic TGCT. 4. Data from the 5 major ITCLC contributors demonstrated convincingly, for the first time, that age-at-diagnosis of familial TGCT is significantly younger than its sproadic counterpart. 5. The final two analyses from this collaboration - (a) quantification of the risk of cancers other than TGCT in multiple-case families, and (b) detailed comparison of the histology of familial versus sporadic TGCT - are underway, with final publications expected within the next 6 months. |